Latest News and Press Releases

Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Cutaneous Lupus Erythematosus Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035"...

Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "Immunotoxins Market by Product, by Application, by End-User, and by Region" report has been added to ResearchAndMarkets.com's offering. This...

AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile Available in the U.S. by Prescription for...

    Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022 Achieved Record Fourth Quarter 2023 Total Revenues of $110.6 Million, an 82.0% Increase Compared to...

Ms. Alicia Grande, Catalyst's Current CFO, to Retire at the End of 2023 Dr. Steven Miller Promoted to Executive Vice President, Chief Operating and Scientific Officer and Jeffrey Del Carmen Promoted...

CORAL GABLES, Fla., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...

CORAL GABLES, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...

CORAL GABLES, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...

Dublin, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The "Ulcerative Colitis Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global ulcerative colitis market is...

Reaffirms Full Year 2023 Total Revenue Guidance of Between $375 Million and $385 Million Forecasts FIRDAPSE® 2023 Net Product Revenue Guidance of Between $245 Million and $255 Million, an...